Joette M. Meyer, Pharm.D.

Acting Medical Team Leader
Division of Special Pathogen and Transplant Products (DSPTP)
Office of Antimicrobial Products, CDER
301-796-0760
joette.meyer@fda.hhs.gov

Dr. Meyer joined the Office of Clinical Pharmacology in CDER as a clinical pharmacologist supporting Division of Special Pathogen and Transplant Products (DSPTP) in 1998 and continued in that position until 2002 when she joined DSPTP as a Clinical Reviewer. Since July 2007, she has also been an Acting Medical Team Leader. 

Dr. Meyer received a B.S. in Pharmacy from the University of Wisconsin-Madison in 1991, and completed a Pharm.D. and General Practice Residency at the University of Washington in Seattle in 1993, followed by a 3-year infectious disease research fellowship at the University of Illinois in Chicago (UIC).  During her fellowship, Dr. Meyer specialized in Helicobacter pylori infections and completed multiple projects from in vitro microbiology studies to clinical trials. Her in vitro work resulted in multiple publications and presentations at various scientific meetings. She also participated as the Principal Investigator and Study Coordinator for original and industry-sponsored clinical trials evaluating various antimicrobials for the treatment of a wide range of infectious diseases. Upon completion of her fellowship, Dr. Meyer was invited to join the faculty at UIC in 1996 as a Clinical Pharmacotherapist and held a joint position between the Colleges of Pharmacy and Medicine in the Departments of Pharmacy Practice and Medicine, Section of Digestive and Liver Diseases. She continued to be active in clinical trials research of infectious and gastrointestinal diseases. Her clinical responsibilities involved providing clinical pharmacy services to the inpatient gastroenterology service at UIC Medical Center, including therapeutic drug monitoring of patients with end-stage liver disease and those post-liver transplant, preceptoring Pharm.D. students and pharmacy residents, and other teaching activities in the College of Pharmacy.

During her 10 years in CDER, Dr. Meyer has preformed reviews INDs and NDAs for a wide range of antimicrobial products, including antibacterial, antifungal, and antiparasitic products, and transplant immunosuppressants, in various capacities. First, as a clinical pharmacologist reviewing Phase 1 pharmacokinetic data, then Phase 2/3 safety and efficacy data as a Clinical Reviewer, and most recently as a secondary reviewer and supervisor of Medical Officers as an Acting Medical Team Leader. She has continued to be recognized in CDER for her knowledge of H. pylori-associated diseases and received an FDA Outstanding Achievement Award in June 2000 for her excellence in the clinical review of H. pylori applications and for making major public health contributions in the area of H. pylori drug development. In May of 2006, Dr. Meyer also received an FDA Outstanding Service Award for her exceptional overall contributions as a clinical reviewer to DSPTP.